Stayble Therapeutics AB (STABL) AI Stock Analysis

• Market Cap: kr10.84M
• Dividend Yield: N/A
• Average Volume (3M): 378.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: N/A
• EPS Growth: 64.02%
• Country: SE
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 64,359,795
• 10 Day Avg. Volume: 398,578
• 30 Day Avg. Volume: 378,512
• PEG Ratio: 0.03
• Price to Book (P/B): 1.92
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: kr0.18 ▼(-27.08% Downside)
• Action: Reiterated Date: 03/01/26
• Date: Action: Reiterated 03/01/26

The score is primarily constrained by pre-revenue fundamentals (ongoing losses and cash burn) and a weakening balance sheet (shrinking equity), partially offset by improving loss and cash burn trends and low leverage. Technicals are also weak with the stock trading below key moving averages, while valuation is limited by negative earnings and no dividend support.

Positive Factors

Targeted, disease-modifying program

A focused pipeline program (STA363) aimed at underlying disc pathology gives the company a clear product strategy and potential clinical differentiation versus symptomatic therapies. This structural therapeutic focus can create durable market positioning if clinical proof points are achieved.

Improving loss and cash burn trends

Narrowing EBIT losses and reduced operating cash burn indicate improving operational efficiency and extend runway without immediate financing. Sustained improvement increases probability of reaching clinical milestones and reduces near-term dilution risk versus a static burn profile.

Very low financial leverage

A zero debt position lowers fixed financial obligations and interest exposure for a pre-revenue biotech. This structural balance-sheet strength improves strategic flexibility for R&D financing, partnerships, or milestone-based funding without debt servicing pressure.

Negative Factors

Pre-revenue commercial risk

Absence of revenue means the firm remains wholly dependent on external capital and development success. Long-term commercial viability hinges on clinical outcomes and successful market entry, making durable cash generation and self-funding unlikely in the near term.

Persistent negative operating cash flow

Ongoing negative operating cash flows require recurrent financing to sustain operations. While burn is improving, continued negative free cash flow preserves structural liquidity risk and may force dilutive financings or partnerships before revenues materialize.

Eroding equity and asset base

A materially shrinking equity and asset base reflects value erosion from sustained losses and weak capitalization. This reduces financial resilience, increases vulnerability to adverse funding conditions, and can impair long-term strategic options including partnering or commercialization.

Stayble Therapeutics AB Business Overview & Revenue Model

Company Description

Stayble Therapeutics AB (STABL) is a clinical-stage pharmaceutical company based in Sweden that focuses on developing innovative treatments for degenerative disc disease and other musculoskeletal disorders. The company is primarily engaged in the research and development of non-surgical therapies that address the underlying causes of chronic back pain, offering potential relief and improved quality of life for patients.

How the Company Makes Money

Stayble Therapeutics AB generates revenue through the development and eventual commercialization of its proprietary treatment solutions for degenerative disc disease. The company primarily invests in clinical trials and research to bring its products to market, aiming to license its technologies to larger pharmaceutical companies upon successful trial results. Significant revenue streams are expected to arise from licensing agreements, milestone payments, and royalties from sales of approved therapies. Partnerships with research institutions and healthcare organizations may also contribute to its earnings by bolstering research capabilities and expanding market reach.

Stayble Therapeutics AB Financial Statement Overview

Summary

Pre-revenue biotech with persistent losses and negative operating cash flow, but with clear improvement in both EBIT (loss narrowing into 2025) and operating cash burn. Balance sheet leverage is low (debt at 0 in 2025), yet shrinking equity and assets signal ongoing financing/dilution risk.

Income Statement

The company reports no revenue across all provided annual periods (2020–2025), consistent with a pre-commercial biotechnology profile. Losses remain sizable, but the loss trend has improved materially: EBIT narrowed from about -24.8M (2022) to -12.8M (2024) and further to -6.9M (2025). Profitability is still weak (net income remains negative every year), and the lack of revenue means the path to self-sustaining earnings is not yet visible from the statements.

Balance Sheet

Leverage is low: total debt is 0 in 2025 (and 0.85M in prior years), with a modest debt-to-equity profile historically. However, the equity base has compressed sharply (about 39.8M in 2021 to ~6.9M in 2025) and total assets have also declined, reflecting sustained losses and cash burn. Returns on equity are deeply negative across the period, highlighting ongoing value erosion despite the relatively clean debt load.

Cash Flow

Operating cash flow is consistently negative, indicating ongoing cash burn (-24.0M in 2020, improving to -6.7M in 2025). Free cash flow is negative in most years (and reported as 0 in 2025, which may reflect reporting/definition rather than true breakeven), so the business is not yet funding itself internally. The improving burn rate is a clear positive, but liquidity risk remains if external funding is required before revenues arrive.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-148.21K	0.00	0.00	0.00
EBITDA	-6.90M	-12.22M	309.41K	-24.50M	-12.03M
Net Income	-6.93M	-12.42M	-23.74M	-24.53M	-12.04M
Balance Sheet
Total Assets	8.62M	9.26M	21.70M	19.15M	43.64M
Cash, Cash Equivalents and Short-Term Investments	2.45M	2.19M	14.08M	12.85M	37.47M
Total Debt	0.00	850.00K	850.00K	850.00K	850.00K
Total Liabilities	1.70M	2.38M	5.19M	3.87M	3.83M
Stockholders Equity	6.92M	6.87M	16.51M	15.28M	39.81M
Cash Flow
Free Cash Flow	0.00	-14.67M	-23.54M	-24.89M	-9.63M
Operating Cash Flow	-6.72M	-14.67M	-23.54M	-24.89M	-9.63M
Investing Cash Flow	0.00	0.00	0.00	1.00K	-1.00K
Financing Cash Flow	6.98M	2.78M	24.96M	1.00K	36.15M

Stayble Therapeutics AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STABL, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.20, and below the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.09 is Neutral, neither overbought nor oversold. The STOCH value of 28.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:STABL.

Stayble Therapeutics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLUI	54 Neutral	kr16.21M	-97.55	-45.97%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STABL	45 Neutral	kr10.84M	-1.92	-84.80%	―	―	64.02%
LARK	43 Neutral	kr42.57M	-1.97	―	8.47%	-94.12%	-25.83%